The VC and Neo products may help us improve a little this quarter. However I am excited re the 3D product. It should be in 10 centres by next quarter and say a usage of 4 patches per week per centre should generate $10m annually. They may discount initially but the companys immediate future is hitched to this unique product and its potential. The other thing is that Europe is a sleeping giant with presently little action. The 3D and Neo products should make in roads soon in Europe. Since we have Paediatric Adapt clearance in Europe I am disappointed re the progress with getting these two new and unique products launched. I hear approval in early 2018 but I like the FDA fast tracking system. Please Mr. Walker fast track these products.
The VC and Neo products may help us improve a little this...
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.33 | $13.91 | $13.14 | $302.2K | 22.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 299 | $13.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.49 | 35 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |